Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Bo Meng, Adam Abdullahi, Isabella A.T.M. Ferreira, +219

Nature

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Rigel Suzuki, Daichi Yamasoba, Izumi Kimura, +74

Nature

Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Daichi Yamasoba, Izumi Kimura, Hesham Nasser, +47

Cell

VaccinationGlobal SpreadBa.2 Spike-bearing VirusViral PersistenceVaccine Development +12

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5

Izumi Kimura, Daichi Yamasoba, Tomokazu Tamura, +41

Cell

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, +20

Cell Reports

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Akatsuki Saito, Tomokazu Tamura, Jiří Zahradník, +46

Cell Host & Microbe

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, +14

South AmericaViral EvolutionEmerging Infectious DiseasesNew VariantPathogenesis +13

Virological characteristics of SARS-CoV-2 BA.2 variant

Daichi Yamasoba, Izumi Kimura, Hesham Nasser, +47

VaccinationGlobal SpreadVaccine DevelopmentViral DiagnosticsEmerging Infectious Diseases +13

Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

Tomokazu Tamura, Takashi Irie, Sayaka Deguchi, +86

Nature Communications

N4BP1 restricts HIV-1 and its inactivation by MALT1 promotes viral reactivation

Daichi Yamasoba, Kei Sato, Takuya Ichinose, +17

Nature Microbiology

Viral ReactivationHuman RetrovirusPathogenesisImmunologyAntiviral Response +7